What is HC Wainwright’s Forecast for RIGL Q3 Earnings?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Stock analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a research note issued to investors on Wednesday, March 5th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings of $0.34 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q4 2025 earnings at $0.48 EPS.

A number of other research analysts have also recently commented on the company. Piper Sandler upped their target price on Rigel Pharmaceuticals from $15.00 to $23.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Citigroup increased their price objective on Rigel Pharmaceuticals from $40.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, November 12th. StockNews.com cut Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. Cantor Fitzgerald increased their price objective on Rigel Pharmaceuticals from $15.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 10th. Finally, B. Riley increased their price objective on Rigel Pharmaceuticals from $20.00 to $24.00 and gave the stock a “neutral” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $35.60.

Rigel Pharmaceuticals Price Performance

Shares of RIGL stock opened at $20.29 on Thursday. The company has a market cap of $357.41 million, a PE ratio of 144.94 and a beta of 1.35. The stock’s 50 day simple moving average is $20.01 and its two-hundred day simple moving average is $18.40. Rigel Pharmaceuticals has a 1 year low of $7.48 and a 1 year high of $29.82.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its quarterly earnings data on Tuesday, March 4th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.50. Rigel Pharmaceuticals had a negative return on equity of 14.80% and a net margin of 2.46%. The business had revenue of $57.60 million for the quarter, compared to the consensus estimate of $57.59 million.

Hedge Funds Weigh In On Rigel Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Rhumbline Advisers raised its stake in shares of Rigel Pharmaceuticals by 6.3% during the 4th quarter. Rhumbline Advisers now owns 25,143 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 1,485 shares during the last quarter. Northern Trust Corp grew its position in shares of Rigel Pharmaceuticals by 1.1% during the 4th quarter. Northern Trust Corp now owns 145,839 shares of the biotechnology company’s stock valued at $2,453,000 after acquiring an additional 1,588 shares during the period. MetLife Investment Management LLC grew its position in shares of Rigel Pharmaceuticals by 19.7% during the 4th quarter. MetLife Investment Management LLC now owns 12,258 shares of the biotechnology company’s stock valued at $206,000 after acquiring an additional 2,014 shares during the period. Geode Capital Management LLC grew its position in shares of Rigel Pharmaceuticals by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 402,051 shares of the biotechnology company’s stock valued at $6,764,000 after acquiring an additional 2,388 shares during the period. Finally, State Street Corp boosted its holdings in Rigel Pharmaceuticals by 0.7% in the 3rd quarter. State Street Corp now owns 367,795 shares of the biotechnology company’s stock worth $5,951,000 after buying an additional 2,552 shares during the last quarter. Hedge funds and other institutional investors own 66.23% of the company’s stock.

Insider Buying and Selling at Rigel Pharmaceuticals

In other news, CFO Dean L. Schorno sold 2,036 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $20.92, for a total transaction of $42,593.12. Following the completion of the sale, the chief financial officer now owns 58,969 shares in the company, valued at approximately $1,233,631.48. This represents a 3.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Raul R. Rodriguez sold 4,952 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $20.92, for a total value of $103,595.84. Following the completion of the transaction, the chief executive officer now owns 243,854 shares of the company’s stock, valued at $5,101,425.68. This trade represents a 1.99 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,113 shares of company stock valued at $190,644. 9.04% of the stock is currently owned by corporate insiders.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.